HN2011003014A - Neocleosidos uracilo espiro ocetano en fecha 16 de noviembre de 2011 se solicita por parte del titular de la invencion modificacion del titulo, ahora se denomina: espironucleosidos uraciclicos oxetanicos - Google Patents
Neocleosidos uracilo espiro ocetano en fecha 16 de noviembre de 2011 se solicita por parte del titular de la invencion modificacion del titulo, ahora se denomina: espironucleosidos uraciclicos oxetanicosInfo
- Publication number
- HN2011003014A HN2011003014A HN2011003014A HN2011003014A HN2011003014A HN 2011003014 A HN2011003014 A HN 2011003014A HN 2011003014 A HN2011003014 A HN 2011003014A HN 2011003014 A HN2011003014 A HN 2011003014A HN 2011003014 A HN2011003014 A HN 2011003014A
- Authority
- HN
- Honduras
- Prior art keywords
- phenyl
- optionally substituted
- owner
- alkyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (1) INCLUYENDO LOS POSIBLES ESTEREOISOMEROS DE LOS MISMOS QUE: R4 ES UN ESTER DE MONOFOSFATO, DIFOSFATO O TRIFOSFATO; Ó R4 ES FORMULA (II) O FORMULA (III), R7 ES OPCIONALMENTE FENILO SUSTITUIDO, OPCIONALMENTE FENILO SUSTITUIDO, OPCIONALMENTE NAFTILO SUSTITUIDO U OPCIONALMENTE INDOLIL SUSTITUID; R8 Y 48 SON HIDROGENO, C1 -C6ALKIL, BENZIL, O FENILO; O FORMA R8 Y R8 C3-C7 CYCLOALIL; ES CL-C10ALKIL, C3-C7CYCLOALKIL, FENILO O FENILO-C1-C6ALKIL, DONDE EL RESTO FENILO EN FENILO O FENILO-C1-C6ALKIL ES OPCIONALMENTE SUSTITUIDO; O UNA SAL FAMACEUTICAMENTE ACEPTABLE O SOLVATO; FORMULAS FARMACEUTICAS Y EL USO DE LOS COMPUESTOS I COMO INHIBIDORES HCV. EN FECHA 16 DE NOVIEMBRE DE 2011, SE SOLICITA POR PARTE DEL TITULAR DE LA INVENCION SE MODIFIQUE EL RESUMEN. "Compuestos de la fórmula 1: incluyendo cualquier estereoisómero posible de los mismos, en donde: R 4 es un éster monofosfato, difosfato o trifosfato; o R 4 es o R7 es fenilo opcionalmente sustituido, naftilo opcionalmente sustituido, o indolilo opcionalmente sustituido; R 8 y R8' are hidrógeno, alquilo C1-C6, bencilo, o fenilo; o R8 y R8' forman cicloalquilo C3--C7; R9 es alquilo C l-C10, cicloalquilo C3-C7, fenilo o fenilalquilo C1-C6, en donde la porción fenilo en el fenilo o en el fenil-alquilo C 1-C6 está opcionalmente sustituida; o una sal o un solvato farmacéuticamente aceptable de los mismos; formulaciones farmacéuticas y el uso de los compuestos 1 como inhibidores del VHC".
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09160215 | 2009-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2011003014A true HN2011003014A (es) | 2014-06-30 |
Family
ID=40823307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2011003014A HN2011003014A (es) | 2009-05-14 | 2011-11-14 | Neocleosidos uracilo espiro ocetano en fecha 16 de noviembre de 2011 se solicita por parte del titular de la invencion modificacion del titulo, ahora se denomina: espironucleosidos uraciclicos oxetanicos |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8481510B2 (es) |
| EP (2) | EP2511282B1 (es) |
| JP (2) | JP5778135B2 (es) |
| KR (1) | KR101806837B1 (es) |
| CN (1) | CN102439024B (es) |
| AP (1) | AP2783A (es) |
| AR (1) | AR076579A1 (es) |
| AU (1) | AU2010247439B2 (es) |
| BR (1) | BRPI1010579A2 (es) |
| CA (1) | CA2760329C (es) |
| CL (1) | CL2011002859A1 (es) |
| CO (1) | CO6440533A2 (es) |
| CR (1) | CR20120297A (es) |
| CY (2) | CY1114081T1 (es) |
| DK (2) | DK2511282T3 (es) |
| EA (1) | EA022084B1 (es) |
| EC (1) | ECSP11011461A (es) |
| ES (2) | ES2477598T3 (es) |
| HK (1) | HK1166326A1 (es) |
| HN (1) | HN2011003014A (es) |
| HR (2) | HRP20130554T1 (es) |
| IL (1) | IL215955A (es) |
| JO (1) | JO3027B1 (es) |
| ME (1) | ME01478B (es) |
| MX (1) | MX2011012027A (es) |
| MY (1) | MY157018A (es) |
| NI (1) | NI201100197A (es) |
| NZ (1) | NZ596073A (es) |
| PL (2) | PL2511282T3 (es) |
| PT (2) | PT2511282E (es) |
| RS (1) | RS52822B (es) |
| SG (1) | SG175981A1 (es) |
| SI (2) | SI2430035T1 (es) |
| SM (2) | SMT201300078B (es) |
| TW (1) | TWI461432B (es) |
| UA (1) | UA105790C2 (es) |
| UY (1) | UY32642A (es) |
| WO (1) | WO2010130726A1 (es) |
| ZA (1) | ZA201108309B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| JO3027B1 (ar) | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
| US9006209B2 (en) | 2010-11-10 | 2015-04-14 | Janssen Products, Lp | Uracyl spirooxetane nucleoside phosphoramidates |
| ES2531583T3 (es) | 2010-11-10 | 2015-03-17 | Janssen Products, L.P. | Fosforamidatos de espironucleósido oxetánico uracílico |
| AU2015252113B2 (en) * | 2010-11-30 | 2017-05-04 | Gilead Pharmasset Llc | Compounds |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| US8877733B2 (en) * | 2011-04-13 | 2014-11-04 | Gilead Sciences, Inc. | 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| EP2861611B1 (en) * | 2012-05-25 | 2016-07-13 | Janssen Sciences Ireland UC | Uracyl spirooxetane nucleosides |
| WO2014135107A1 (zh) | 2013-03-08 | 2014-09-12 | 南京圣和药业有限公司 | 新的核苷氨基磷酸酯化合物及其应用 |
| US20140309164A1 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating hcv |
| WO2014194826A1 (zh) * | 2013-06-06 | 2014-12-11 | 南京圣和药业有限公司 | 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用 |
| AU2013406644B2 (en) * | 2013-11-28 | 2018-04-05 | Janssen Sciences Ireland Uc | Crystal form of nucleoside inhibitor of HCV |
| EP3265102A4 (en) | 2015-03-06 | 2018-12-05 | ATEA Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| SG10202012214WA (en) | 2017-02-01 | 2021-01-28 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
| US12110308B2 (en) | 2018-01-10 | 2024-10-08 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| TW202012001A (zh) | 2018-04-10 | 2020-04-01 | 美商亞堤製藥公司 | C型肝炎病毒(hcv)感染硬化之患者的治療 |
| US12110311B2 (en) | 2019-07-17 | 2024-10-08 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2021255811A1 (en) * | 2020-04-14 | 2022-12-22 | Janssen Pharmaceuticals, Inc | Spirocyclic nucleoside analogues for the treatment of hepatitis E |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2434386C (en) * | 2001-01-22 | 2006-12-05 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| US20070265222A1 (en) * | 2004-06-24 | 2007-11-15 | Maccoss Malcolm | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection |
| CA2618335C (en) * | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
| JP2009526850A (ja) * | 2006-02-14 | 2009-07-23 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート |
| PA8852101A1 (es) * | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
| JO3027B1 (ar) * | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
-
2010
- 2010-05-04 JO JOP/2010/0138A patent/JO3027B1/ar active
- 2010-05-11 EP EP12176402.1A patent/EP2511282B1/en active Active
- 2010-05-11 PT PT121764021T patent/PT2511282E/pt unknown
- 2010-05-11 SG SG2011082757A patent/SG175981A1/en unknown
- 2010-05-11 ME MEP-2013-47A patent/ME01478B/me unknown
- 2010-05-11 EA EA201171406A patent/EA022084B1/ru not_active IP Right Cessation
- 2010-05-11 MY MYPI2011005445A patent/MY157018A/en unknown
- 2010-05-11 AU AU2010247439A patent/AU2010247439B2/en not_active Ceased
- 2010-05-11 RS RS20130213A patent/RS52822B/en unknown
- 2010-05-11 NZ NZ596073A patent/NZ596073A/xx not_active IP Right Cessation
- 2010-05-11 PL PL12176402T patent/PL2511282T3/pl unknown
- 2010-05-11 EP EP10718207A patent/EP2430035B1/en active Active
- 2010-05-11 SI SI201030246T patent/SI2430035T1/sl unknown
- 2010-05-11 JP JP2012510269A patent/JP5778135B2/ja not_active Expired - Fee Related
- 2010-05-11 DK DK12176402.1T patent/DK2511282T3/da active
- 2010-05-11 KR KR1020117029826A patent/KR101806837B1/ko active IP Right Grant
- 2010-05-11 PL PL10718207T patent/PL2430035T3/pl unknown
- 2010-05-11 ES ES12176402.1T patent/ES2477598T3/es active Active
- 2010-05-11 PT PT107182073T patent/PT2430035E/pt unknown
- 2010-05-11 WO PCT/EP2010/056438 patent/WO2010130726A1/en active Application Filing
- 2010-05-11 CA CA2760329A patent/CA2760329C/en active Active
- 2010-05-11 MX MX2011012027A patent/MX2011012027A/es active IP Right Grant
- 2010-05-11 ES ES10718207T patent/ES2411086T3/es active Active
- 2010-05-11 AP AP2011005958A patent/AP2783A/xx active
- 2010-05-11 CN CN201080021188.8A patent/CN102439024B/zh active Active
- 2010-05-11 SI SI201030667T patent/SI2511282T1/sl unknown
- 2010-05-11 DK DK10718207.3T patent/DK2430035T3/da active
- 2010-05-11 US US13/319,735 patent/US8481510B2/en active Active
- 2010-05-11 BR BRPI1010579A patent/BRPI1010579A2/pt active Search and Examination
- 2010-05-12 TW TW099115051A patent/TWI461432B/zh not_active IP Right Cessation
- 2010-05-13 AR ARP100101670A patent/AR076579A1/es unknown
- 2010-05-14 UY UY0001032642A patent/UY32642A/es unknown
- 2010-11-05 UA UAA201112920A patent/UA105790C2/uk unknown
-
2011
- 2011-10-26 IL IL215955A patent/IL215955A/en not_active IP Right Cessation
- 2011-10-27 CO CO11145588A patent/CO6440533A2/es not_active Application Discontinuation
- 2011-11-11 ZA ZA2011/08309A patent/ZA201108309B/en unknown
- 2011-11-11 NI NI201100197A patent/NI201100197A/es unknown
- 2011-11-14 EC EC2011011461A patent/ECSP11011461A/es unknown
- 2011-11-14 HN HN2011003014A patent/HN2011003014A/es unknown
- 2011-11-14 CL CL2011002859A patent/CL2011002859A1/es unknown
-
2012
- 2012-05-30 CR CR20120297A patent/CR20120297A/es unknown
- 2012-07-18 HK HK12107046.5A patent/HK1166326A1/xx unknown
-
2013
- 2013-03-15 US US13/836,465 patent/US8933052B2/en active Active
- 2013-05-22 CY CY20131100408T patent/CY1114081T1/el unknown
- 2013-06-18 HR HRP20130554AT patent/HRP20130554T1/hr unknown
- 2013-07-04 SM SM201300078T patent/SMT201300078B/xx unknown
-
2014
- 2014-06-26 HR HRP20140605AT patent/HRP20140605T1/hr unknown
- 2014-06-30 SM SM201400085T patent/SMT201400085B/xx unknown
- 2014-07-01 CY CY20141100491T patent/CY1115383T1/el unknown
-
2015
- 2015-07-06 JP JP2015135001A patent/JP2015180692A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2011003014A (es) | Neocleosidos uracilo espiro ocetano en fecha 16 de noviembre de 2011 se solicita por parte del titular de la invencion modificacion del titulo, ahora se denomina: espironucleosidos uraciclicos oxetanicos | |
| UY32308A (es) | Nucleótidos uracil ciclopropílicos | |
| ECSP10010725A (es) | Inhibidores de ciclopropil-polimerasa | |
| UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
| CR11683A (es) | Piridinas y pirazinas como inhibidores de p13k | |
| UY30527A1 (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| AR057812A1 (es) | Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas | |
| ECSP12011947A (es) | Inhibidores macrocíclicos de serina proteasas de hepatitis c | |
| CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| NI201000119A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis. | |
| ECSP077649A (es) | Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| NI201200059A (es) | PIPERIDINAS SUSTITUIDAS QUE AUMENTAN LA ACTIVIDAD DE p53 Y SUS USOS | |
| UY30391A1 (es) | Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c | |
| AR073603A1 (es) | Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido | |
| CR10376A (es) | Derivados de terfenil para el tratamiento de la enfermedad de alzheimer | |
| AR077869A1 (es) | Forma cristalina de tiazolpirrolidin propionamida como inhibidor de la proteina de apoptosis: formulaciones farmaceuticas | |
| PE20080687A1 (es) | Derivados de iminoimidazopiridina que tienen actividad antitrombotica | |
| TH112183B (th) | สารยับยั้งไซโคลโพรพิล พอลิเมอเรส | |
| AR079266A1 (es) | Derivados de azabiciclo[3.2.0]hept-6ilo, procedimiento de preparacion de los mismos, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| UY31262A1 (es) | Compuestos de biciclolactama sustituida | |
| HN2010000739A (es) | Inhibidores de quinasa c-fms | |
| AR060285A1 (es) | Derivados de enfumafungina y sus sales farmaceuticamente aceptables, su sintesis y su uso como inhibidores de (1,3)-b-d-glucanosintetasa |